ESR1 and breast cancer: Recent studies have reported that 4-hydroxytamoxifen (4-OHT) induces ACSS1 and ACSS2 mRNA and protein expression in estrogen receptor-α-positive (ER+) breast cancer cells and derived 4-OHT-resistant cells to increase their survival.